Search Results - "Sotelo, Jilliane"

Tumor-Based Genetic Testing and Familial Cancer Risk by Forman, Andrea, Sotelo, Jilliane

“…As genetic testing on somatic tumor tissue becomes a more routine part of personalized cancer treatment, a growing opportunity arises to identify hereditary…”
Get full text

Genetic counselors’ comfort and knowledge of cancer risk assessment for transgender patients by Berro, Tala, Zayhowski, Kimberly, Field, Tessa, Channaoui, Nadine, Sotelo, Jilliane

“…Transgender individuals are often their own health advocates, especially if seeking hormone therapies and gender‐affirmation surgeries. While literature exists…”
Get full text

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program by Bychkovsky, Brittany L, Li, Tianyu, Sotelo, Jilliane, Tayob, Nabihah, Mercado, Joanna, Gomy, Israel, Chittenden, Anu, Kane, Sarah, Stokes, Samantha, Hughes, Melissa E, Kim, Ji Seok, Umeton, Renato, Awad, Mark M, Konstantinopoulos, Panagiotis A, Yurgelun, Matthew B, Wolpin, Brian M, Taplin, Mary-Ellen, Newmark, Randall E, Johnson, Bruce E, Lindeman, Neal I, MacConaill, Laura E, Garber, Judy E, Lin, Nancy U

“…Tumor-only genomic testing can uncover somatic and germline pathogenic variants [pathogenic/likely pathogenic (P/LP)] in cancer predisposition genes. We…”
Get full text

Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program by Bychkovsky, Brittany L., Li, Tianyu, Sotelo, Jilliane, Tayob, Nabihah, Mercado, Joanna, Gomy, Israel, Chittenden, Anu B., Kane, Sarah R., Stokes, Samantha, Hughes, Melissa E, Kim, Ji Seok, Awad, Mark M., Konstantinopoulos, Panagiotis A., Wolpin, Brian M., Taplin, Mary-Ellen, Johnson, Bruce E., Lindeman, Neal Ian, MacConaill, Laura E, Garber, Judy Ellen, Lin, Nancy U.

“…Abstract only 10528 Background: Tumor-genomic testing is increasingly used to guide treatment decisions in cancer patients. Although tumor-only testing cannot…”
Get full text

Beyond BRCA1/2: Clinician-reported utility 3 years post panel testing by Esplin, Edward D., Chittenden, Anu B., Stopfer, Jill, Schneider, Katherine, Sacca, Rosalba, Stickevers, Samantha, Kipnis, Lindsay, Koeller, Diane R., Gaonkar, Shraddha, Sotelo, Jilliane, Espinel, Whitney, Champine, Marjan, Westman, Judith, Brock, Pamela, Shane-Carson, Kate P., Pearlman, Rachel, Pilarski, Robert, Sweet, Kevin, Jeter, Joanne M., Hampel, Heather

“…Abstract only…”
Get full text

Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients by Espinel, Whitney, Champine, Marjan, Hampel, Heather, Jeter, Joanne, Sweet, Kevin, Pilarski, Robert, Pearlman, Rachel, Shane, Kate, Brock, Pamela, Westman, Judith A, Kipnis, Lindsay, Sotelo, Jilliane, Chittenden, Anu, Culver, Samantha, Stopfer, Jill E, Schneider, Katherine A, Sacca, Rosalba, Koeller, Diane R, Gaonkar, Shraddha, Vaccari, Erica, Kane, Sarah, Michalski, Scott T, Yang, Shan, Nielsen, Sarah M, Bristow, Sara L, Lincoln, Stephen E, Nussbaum, Robert L, Esplin, Edward D

“…Consensus guidelines for hereditary breast and ovarian cancer include management recommendations for pathogenic/likely pathogenic (P/LP) variants in , , and…”
Get full text